| pubmed-article:12820476 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12820476 | lifeskim:mentions | umls-concept:C0227598 | lld:lifeskim |
| pubmed-article:12820476 | lifeskim:mentions | umls-concept:C0007138 | lld:lifeskim |
| pubmed-article:12820476 | lifeskim:mentions | umls-concept:C0069717 | lld:lifeskim |
| pubmed-article:12820476 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:12820476 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
| pubmed-article:12820476 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:12820476 | pubmed:issue | 2C | lld:pubmed |
| pubmed-article:12820476 | pubmed:dateCreated | 2003-6-24 | lld:pubmed |
| pubmed-article:12820476 | pubmed:abstractText | Despite the fact that new drugs have emerged from clinical research in urothelial cancer during the last decade, the prognosis of patients with advanced disease remains poor with a median survival of 12 to 14 months. We designed a feasibility study of gemcitabine and oxaliplatin (GO) in patients with advanced urothelial cancer. | lld:pubmed |
| pubmed-article:12820476 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12820476 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12820476 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12820476 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12820476 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12820476 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12820476 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12820476 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12820476 | pubmed:issn | 0250-7005 | lld:pubmed |
| pubmed-article:12820476 | pubmed:author | pubmed-author:CulineStéphan... | lld:pubmed |
| pubmed-article:12820476 | pubmed:author | pubmed-author:PinguetFrédér... | lld:pubmed |
| pubmed-article:12820476 | pubmed:author | pubmed-author:MottetNicolas... | lld:pubmed |
| pubmed-article:12820476 | pubmed:author | pubmed-author:RebillardXavi... | lld:pubmed |
| pubmed-article:12820476 | pubmed:author | pubmed-author:IborraFrancoi... | lld:pubmed |
| pubmed-article:12820476 | pubmed:author | pubmed-author:FaixAntoineA | lld:pubmed |
| pubmed-article:12820476 | pubmed:author | pubmed-author:AyusoDidierD | lld:pubmed |
| pubmed-article:12820476 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12820476 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:12820476 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12820476 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12820476 | pubmed:pagination | 1903-6 | lld:pubmed |
| pubmed-article:12820476 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:meshHeading | pubmed-meshheading:12820476... | lld:pubmed |
| pubmed-article:12820476 | pubmed:articleTitle | Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study. | lld:pubmed |
| pubmed-article:12820476 | pubmed:affiliation | Department of Medical Oncology, C.R.L.C. Val d'Aurelle, Parc Euromédecine, 34598-Montpellier, France. stculine@valdorel.fnclcc.fr | lld:pubmed |
| pubmed-article:12820476 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12820476 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12820476 | lld:pubmed |
